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Abstract
Objectives—To evaluate the durations of
the follow up and the reference population
sizes needed to achieve optimal and stable
statistical powers for two period cross over
and parallel group design clinical trials in
multiple sclerosis, when using the num-
bers of new enhancing lesions and the
numbers of active scans as end point vari-
ables.
Methods—The statistical power was cal-
culated by means of computer simulations
performed using MRI data obtained from
65 untreated relapsing-remitting or sec-
ondary progressive patients who were
scanned monthly for 9 months. The statis-
tical power was calculated for follow up
durations of 2, 3, 6, and 9 months and for
sample sizes of 40–100 patients for parallel
group and of 20–80 patients for two period
cross over design studies. The stability of
the estimated powers was evaluated by
applying the same procedure on random
subsets of the original data.
Results—When using the number of new
enhancing lesions as the end point, the
statistical power increased for all the
simulated treatment eVects with the dura-
tion of the follow up until 3 months for the
parallel group design and until 6 months
for the two period cross over design. Using
the number of active scans as the end
point, the statistical power steadily in-
creased until 6 months for the parallel
group design and until 9 months for the
two period cross over design. The power
estimates in the present sample and the
comparisons of these results with those
obtained by previous studies with smaller
patient cohorts suggest that statistical
power is significantly overestimated when
the size of the reference data set decreases
for parallel group design studies or the
duration of the follow up decreases for two
period cross over studies.
Conclusions—These results should be
used to determine the duration of the fol-
low up and the sample size needed when
planning MRI monitored clinical trials in
multiple sclerosis.
(J Neurol Neurosurg Psychiatry 1999;66:465–469)
Keywords: multiple sclerosis; magnetic resonance imag-
ing; power calculations; treatment trials
Brain MRI is the optimal technique for the
diagnosis of multiple sclerosis. It also provides
an objective and sensitive measure for monitor-
ing disease evolution, either natural or modi-
fied by treatment.1 2 Monthly brain MRI
detects active multiple sclerosis lesions five to
10 times more often than the occurrence of
clinical relapses in patients with early
relapsing-remitting and secondary progressive
multiple sclerosis.3 This high sensitivity of MRI
is mainly based on its high sensitivity in detect-
ing gadolinium (Gd) enhancing lesions.4 This
is why to evaluate the eYcacy of an experimen-
tal treatment in multiple sclerosis, the most
widely used end points are the counts of
enhancing lesions or scans with at least one of
such lesions.5 6
The costs of clinical trials based on MRI
derived outcome measures are significantly
aVected by the numbers of scans needed,
which in turn depends on the number of
patients enrolled, the duration of the trial, and
the frequency of MRI sampling. It was shown
that with a given treatment eYcacy and sample
size, the power of the trial increases with
increasing duration of the follow up.6 However,
this increase is not linear and, after a certain
number of months, the gain in power increases
more slowly.6 Thus the advantage of having a
more powerful study might not counterbalance
the increased costs. At present, no formal study
evaluating the appropriate durations of such
trials has been performed. In addition, previous
statistical simulations6–8 were based on rela-
tively small data sets and this may result in an
overestimation of the calculated power due to
the resampling methodology used. In the
present study, we performed simulations using
a larger patient data set to calculate the gain in
statistical power of two period cross over and
parallel group design trials with increasing trial
durations. In this patients’ cohort, we also
evaluated the number of patients and the dura-
tion of follow up period needed to obtain rela-
tively stable power estimates. The ultimate goal
of this study was to provide a rational basis to
calculate the duration of clinical trials in multi-
ple sclerosis when using enhanced MRI
derived end points.
Patients and methods
PATIENTS
Sixty five patients (47 women and 18 men)
with clinically definite multiple sclerosis9 were
selected from five European centres (eight
patients were recruited in Amsterdam, 32 in
London, six in Milan, nine in Munich, and 10
in Rome). According to recently published
criteria,10 the cohort consisted of 43 patients
with relapsing-remitting multiple sclerosis and
22 patients with secondary progressive
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multiple sclerosis. The median age at entry was
33 years (range 15 to 61 years) and median
disease duration was 4 years (range 1 to 28
years). Patients were either involved in natural
history studies (43 patients) or formed the pla-
cebo arms of previous treatment trials (22
patients). The overall patients’ characteristics
at entry were similar to those of patients usually
recruited for MRI monitored trials in multiple
sclerosis. To be included, patients had to have
had serial monthly gadolinium enhanced T1
weighted scans for at least 9 months with a T2
weighted scan at study entry and exit. Patients
taking immunosuppressive drugs other than
infrequent courses of corticosteroids during
relapses were excluded. No patients with
relapsing-remitting multiple sclerosis entered
the secondary progressive phase of the disease
during the follow up.
MRI
Serial T2 weighted conventional spin echo
(CSE) or fast spin echo (FSE) MR images were
acquired at study entry and exit. T1 weighted
imaging 5–15 minutes after injection of gado-
linium was also performed monthly through-
out the study period. Conventional dose
gadolinium-DTPA (0.1 mmol/kg) was given in
56 of 65 patients, the other nine patients, all
recruited in Munich, received 0.2 mmol/kg.
Gadolinium enhanced images were not per-
formed within 1 week of corticosteroid treat-
ment.
In Amsterdam, CSE images were obtained
using a 0.6 Tesla Technicare (Teslacon II)
scanner (SE 2755/60 at entry and exit, SE
450/28 for enhanced scans, 5 mm contiguous
axial slices with an interslice gap of 1.25 mm).
In London, all MRI was performed using a GE
1.5 Tesla scanner with either CSE (14 patients,
2000/34 at entry and exit, SE 640/14 for
enhanced scans, 5 mm contiguous axial slices)
or FSE (18 patients, SE 3500/18 at entry and
exit, SE 579/19 or 580/13 for enhanced scans,
4 mm contiguous axial slices). In Milan, a Sie-
mens 1.5 Tesla machine was used to obtain
CSE images (SE 2000/50 at entry and exit, SE
768/15 for enhanced scans, 5 mm contiguous
axial slices). In Munich, images were obtained
on a Siemens Impact scanner operating at 1.0
Tesla (SE 3000/40 at entry and exit, SE 600/28
for enhanced scans, 5 mm contiguous axial
slices). In Rome, a 0.5 T Toshiba machine was
used to obtain CSE images (SE 2500/30 at
entry and exit, 400/18 for enhanced scans, 5
mm contiguous axial slices with an interslice
gap of 1.0 mm). The scanners used are
representative of those typically used in multi-
centre multiple sclerosis studies. The intercen-
tre variability in the MRI acquisition param-
eters was slightly larger than that usually
allowed in MRI monitored clinical trials, and
reflected the post hoc nature of the present
study (this might have resulted in a slight over-
estimation of the power estimates). Scanners
were not changed or upgraded over the
duration of the study and image acquisition
parameters were not modified between entry
and exit. The numbers of total and new
enhancing lesions were counted on monthly
scans by experienced observers at each indi-
vidual centre.
COMPUTER SIMULATIONS
The results of MRI monitored clinical trials are
usually analysed by means of non-parametric
tests.6 In such a context, computer simulations
are needed to calculate sample sizes. In the
present study, computer simulations were per-
formed according to the method used by Nauta
et al,6 Truyen et al,7 and Tubridy et al,8 consid-
ering only the case of a homogeneous
response.8 The number of new enhancing
lesions and the number of active scans were
considered the end point variables. According
Table 1 Estimated statistical powers required for parallel
group trials using diVerent sample sizes and durations of
follow up for diVerent treatment eVects using the number of
new enhancing lesions (A.III) and the number of active
scans (A.II) as the end point measure
Sample
size
EVect
(%)
Response
variable
Duration of follow up (months)
2 3 6 9
2×20 50 A.II 13 13 14 15
A.III 14 17 19 21
60 A.II 20 21 24 25
A.III 28 35 37 37
70 A.II 31 35 40 43
A.III 37 54 57 57
2×30 50 A.II 16 18 21 22
A.III 22 27 30 31
60 A.II 27 31 36 39
A.III 43 48 50 54
70 A.II 45 51 58 60
A.III 55 71 74 75
2×40 50 A.II 21 23 27 29
A.III 26 33 38 40
60 A.II 36 39 46 48
A.III 54 62 62 67
70 A.II 57 64 71 72
A.III 69 83 85 87
2×50 50 A.II 24 27 32 34
A.III 31 41 46 46
60 A.II 43 48 55 58
A.III 63 67 74 74
70 A.II 69 73 80 81
A.III 76 90 92 92
Table 2 Estimated statistical powers required for two
period cross over trials using diVerent sample sizes and
durations of follow up for diVerent treatment eVects using
the number of new enhancing lesions (A.III) and the
number of active scans (A.II) as the end point measure
Sample
size
EVect
(%)
Response
variable
Duration of each treatment period
(months)
2 3 6 9
2×10 30 A.II 3 7 16 19
A.III 22 35 62 76
40 A.II 3 7 16 21
A.III 37 55 83 91
50 A.II 10 19 40 49
A.III 56 73 93 98
2×20 30 A.II 27 36 43 52
A.III 51 69 91 98
40 A.II 31 39 47 55
A.III 77 91 92 100
50 A.II 54 70 82 89
A.III 92 98 100 100
2×30 30 A.II 49 50 58 70
A.III 69 87 98 100
40 A.II 50 52 63 73
A.III 92 98 100 100
50 A.II 79 83 93 98
A.III 99 100 100 100
2×40 30 A.II 52 57 68 79
A.III 81 95 100 100
40 A.II 57 60 73 85
A.III 97 100 100 100
50 A.II 85 91 98 100
A.III 100 100 100 100
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to previous studies,6–8 we indicated as response
variable A.II the number of active scans and as
response variable A.III the number of new
enhancing lesions. The 65 patients studied for
9 months were considered representative of the
“untreated” multiple sclerosis population. The
first stage of the simulation process consisted in
simulating the treatment eVect. For each lesion
observed in the “untreated” group (and for
each active scan) a Bernoulli trial with a prob-
ability for success set to the desired treatment
eVect was performed; a success consisted of the
disappearance of the lesion (or of the entire
activity on individual scans). In this way, a
treated group was created for each treatment
eVect. It is assumed that the experimental
treatment becomes eVective immediately and
its eYcacy does not change during follow up.
The second stage of the simulation consisted of
generating 1000 trials for each study design.
The trials were simulated by drawing random
sets of diVerent size from the data (sampling
with replacement). The power for parallel
group design and the two period cross over
design for follow up durations of 2, 3, 6, and 9
months was calculated as the proportion of
trials which yielded a significant result. To
evaluate the number of patients and the
duration of follow up periods needed to achieve
relatively stable estimates of the study power,
we applied the same statistical approach to
random subsets of the original data set (10, 25,
and 40 patients with 9 months of follow up for
the parallel group design and all the available
patients with 3 and 6 months of follow up for
the two period cross over design). The statisti-
cal tests used in simulations were the Wilcoxon
signed rank test for the two period cross over
design and the Wilcoxon rank sum test for the
parallel group design.
Results
A total of 585 scans were obtained during the
study period: 316 (54%) had one or more
enhancing lesions (active scans). Nine patients
had no enhancement for the entire study
period, whereas 10 patients had always active
scans. The total number of enhancing lesions
was 1436: the mean number of enhancing
lesions/patient/scan was 2.4 (range= 0–53).
The power of the parallel group design trials
is presented in table 1. For each treatment
eVect, the statistical power of the trial increased
with the duration of the follow up until 3
months duration, when using the number of
new enhancing lesions as the end point (A.III).
For instance, with an expected treatment effect
of 70%, depending on the sample size, the
absolute increase in statistical power of the trial
was 14%–17% from 2 to 3 months of follow up
duration and was 2% to 3% from 3 to 6 months
duration, whereas no further gain in power was
obtained from 6 to 9 months of follow up
duration. When simulations were performed
using the proportions of active scans as the end
point (A.II), a similar trend was found, but the
gain in statistical power was lower. For
instance, for a treatment eVect of 70% we
found, depending on the sample sizes, an
increase in statistical power of 4%–7% from 2
to 3 months of follow up duration, by 5%–7%
from 3 to 6 months of follow up duration and
by 1%–3% from 6 to 9 months of follow up
duration.
The power of two period cross over trials are
presented in the table 2. For this study design,
the statistical power increased considerably
with increasing duration of the follow up for
both the variables studied (A.II and A.III). For
instance, for an expected treatment eVect of
30% and a sample size of 2×10 patients, the
power increased by 13% from 2 to 3 months of
follow up duration, by 27% from 3 to 6 months
of follow up durations, and by 14% from 6 to 9
months of follow up duration. However, for
higher treatment eVects, no further gain in
power was seen after 6 months of scanning,
whereas, using active scans as the end point
variable, the statistical power steadily increased
until 9 months.
To test the simulation method performance
and the stability of power estimates, we
performed the same simulations by applying
the resampling procedure on subsets of data
randomly selected from the original data set
and using A.III as the response variable. In
table 3, the results for the parallel group design
are reported. Firstly, we extracted random sub-
sets of 10, 25, and 40 patients, each with 9
Table 3 Estimated statistical powers required for parallel
group trials for a 70% treatment eVect using variable
numbers of patients for the reference data set. The duration
of follow up was 9 months and the tested response variable
was the number of new enhancing lesions
Sample size
Number of patients used for simulations
10 25 40 65
2×20 74 72 62 57
2×30 89 88 78 75
2×40 96 93 88 87
2×50 99 94 96 92
Table 4 Estimated statistical powers required for two
period cross over trials for a 20% treatment eVect using
variable durations of follow up for the reference data set.
The simulated duration of follow up was 3 months for each
period and the tested response variable was the number of
new enhancing lesions
Sample size
Number of months used for simulations
3 6 9
2×10 27 25 23
2×20 67 47 41
2×30 77 71 56
2×40 89 73 64
Table 5 Comparison of the results obtained in four studies
using the same simulation approach in computing the
statistical power for a parallel group design with follow up
duration of 6 months and for expected treatment eVects of
60% and 70%. The response variable studied was the
number of new enhancing lesions
Sample
size
Truyen
et al7
(n=12)
Nauta
et al6
(n=23)
Tubridy
et al8
(n=31)
Present study
(n=65)
2×10 60 - - - 35
70 84 71 61 57
2×20 60 80 70 63 50
70 93 88 81 74
2×30 60 89 78 72 62
70 99 95 89 85
2×40 60 94 87 83 74
70 99 100 95 92
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months of follow up, for the reference data set
used to calculate the powers of parallel group
trials. The power was calculated for an
expected treatment eVect of 70% and for
diVerent sample sizes. The power was increas-
ingly overestimated when sampling from
smaller data sets. Secondly, for the two period
cross over design (table 4), subsets of 3 and 6
months of follow up were selected for the
reference data set. The power was calculated
for an expected treatment eVect of 20% for dif-
ferent sample sizes with 3 months of follow up.
Again, power steadily decreased with increas-
ing the durations of follow up periods. These
findings were confirmed by comparing the
power estimates of the present study with those
obtained by previous studies,6–8 based on
smaller sample sizes (table 5).
Discussion
In this study, we aimed to find out the optimal
duration of follow up of MRI monitored clini-
cal trials, with the minimum number of scans
required to achieve a desired statistical power,
when the end point variables are the number of
new enhancing lesions and the number of
active scans. We also investigated the perform-
ance of the computer simulation procedure
adopted if applied to smaller data sets. The
main result of the study is that when the end
point variable is the number of new enhancing
lesions as detected by monthly MRI, there is
little gain in collecting more than three
monthly scans for each patient for parallel
group design trials, whereas six scans per
patient for each treatment period are more
desirable when planning two period cross over
studies.
For the parallel group design, the statistical
power increases very slowly when collecting
more than three scans per patient. When such
a study design is used, the factor that mainly
aVects the statistical power is the between sub-
ject variability, which is not substantially
reduced by increasing the follow up duration.
As already pointed out by Nauta et al,6 adding
up scans for a patient participating in a trial
may just result in adding correlated infor-
mation, which may be redundant to existing
information. Thus as our simulations indicate,
when planning parallel group design trials, it is
more desirable to enroll a larger number of
patients to be followed up for a period no
longer than 3 months rather than enrolling
fewer patients and following them up for longer
periods.
On the contrary, for two period cross over
design studies, the duration of the follow up
clearly has a higher influence on the statistical
power. In this case, the within patient variabil-
ity is less of an issue, whereas patients with no
enhancing lesions in the pretreatment period
have a crucial role in determining the power of
the study. These patients can, in fact, either
increase the number of enhancing lesions or, at
least, continue to be inactive during the
treatment period and they do not have any
possibility of “doing better” on treatment.
Therefore, increasing the follow up durations
increases the likelihood of finding an active
scan in the pretreatment period, and, as a con-
sequence, increases the likelihood of observing
a treatment eVect.
At present, computer simulations are the
approach used to calculate sample sizes for
multiple sclerosis trials, when the end point is
lesion counting on MRI. The method we used,
firstly proposed by Nauta et al,6 has the advan-
tage of being independent from any assump-
tion about the distribution of lesion counts. In
fact, the simulated treatment eVect is not
performed on population parameters (for
example, a lesion appearance rate) and their
related distributions, but directly on the
observed lesion number of each patient in the
data set. The set of “treated” patients is, in fact,
the same as the “untreated” set, but with
reduced lesion numbers. Therefore, by simu-
lating the treatment as described above, a
patient can only “do better” after the treatment
initiation, whereas this is not the case in the
daily life situation even in the case of very
eVective treatments. Thus it is not surprising
that such a method works better when using
large data sets from which performing the
repeated sampling procedure.
The statistical power of trials is likely to be
overestimated by this approach, when resam-
pling from small patient cohorts for parallel
group design trials or larger cohorts with short
follow up periods for cross over design trials.
For parallel group design trials, resampling
from the same small cohort of patients would
inevitably lead to the formation of two groups
(treated and untreated) made up almost by the
same subjects. Thus the between subject
variability would be artificially lost with, as a
consequence, a power overestimation. The
same is true for crossover design trials when
resampling from groups of patients with short
follow up periods; in this case, the artificial
reduction of the within subject variability
would also result in power overestimation. A
parametric simulation might be a preferable
approach to sample size calculations for MRI
monitored trials in multiple sclerosis. This
might be obtained by resampling from a theo-
retical population using a fitted model. At
present, however, no parametric model has
been proposed to describe MRI lesion counts
in multiple sclerosis. Therefore, we consider
this issue a desirable future development in this
area.
Table 5, which shows a comparison with
previous studies,6–8 confirms this issue. For this
comparison, we chose the data calculated for
the parallel group design with a duration of fol-
low up of 6 months, as this is analysed by all the
authors. The statistical power decreases with
the size of the patients’ reference data set used
for resampling. For instance, the statistical
power computed by Truyen et al,7 who used a
data set of 12 patients, is 30% higher than the
power computed in the present study. Al-
though we cannot exclude that these diVer-
ences may be due, at least partially, to the dif-
ferent samples used (for example, diVerent
frequency of enhancement and proportions of
active scans, diVerent patient clinical sub-
groups studied, etc), the trend observed
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suggests that there is a lower limit in the
number of patients and in the duration of
follow up needed to perform an adequate
resampling procedure.
The power estimates we obtained in the
present study are clearly dependent on the
characteristics of the patients’ sample used as
the reference data set and the MRI procedures
used. Therefore, it would be desirable to
develop an ad hoc computer program that
could be used when setting up clinical trials to
calculate the needed sample sizes on the basis
of the local data. Nevertheless, the clinical char-
acteristics of the patients we studied are similar
to those of patients usually recruited for MRI
monitored trials in multiple sclerosis. Similarly,
the range of the MRI scanners used in this study
was comparable with that of previously per-
formed multicentre clinical trials in multiple
sclerosis.11 On the contrary, the MRI acquisition
parameters used in the present study were
somewhat more flexible than those allowed in
clinical trials, and reflected the post hoc nature
of the present study. This increased heterogen-
eity in data acquisition should, however, make
our power estimates more conservative.
Recent studies have shown that the use of
diVerent MR techniques may result in a higher
detection of enhancing lesions and active
scans,2 which might further increase the power
of MR monitored clinical trials or require even
smaller sample sizes or shorter follow up dura-
tions. An important caveat is that the duration
of the follow up period should not only be
determined by statistical considerations, but
should also be based on the characteristics of
the experimental treatment used. In fact,
although studies with small sample sizes or
short follow up periods may have enough
statistical power, it is more likely that a small
sample size will not be as fully representative of
the response subsequently found in the general
multiple sclerosis population, and that very
short term follow up periods may miss a treat-
ment eVect that takes several months to
develop. This is particularly true when consid-
ering that the simulation procedure is based on
the assumption that an experimental treatment
becomes immediately eVective and has a
constant eYcacy over time. Therefore, in the
case of treatments known to become eVective
after a certain period of time, it is advisable
either to ignore the first scans collected or to
delay the scanning period after treatment
initiation. Small, short term studies will also
have less opportunity for detecting relevant
side eVects. Finally a very short term study may
fail to detect an earlier failure of treatment—for
example, the number of enhancing lesions rises
again after a few months due to the develop-
ment of an antidrug antibody.
In conclusion, this study provides stable esti-
mates of the optimal durations of the follow up
needed for two period cross over and parallel
group design studies. It suggests that, contrary
to conventional wisdom, which suggests that at
least six scans per patient should be obtained,
only three scans per patient are needed when
performing parallel group studies.
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